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The resistance of adult immunocompetent mice to infection with ebolaviruses has led to the develop-
ment of alternative small animal models that utilise immunodeﬁcient mice, for example the interferon
α/β receptor knock-out mouse (IFNR−/−). IFNR−/− mice have been shown to be susceptible to infection
with ebolaviruses by multiple routes but it is not known if this murine model is suitable for testing
therapeutics that rely on the generation of an immune response for efﬁcacy. We have tested recombinant
adenovirus vectors for their ability to protect IFNR−/− mice from challenge with Ebola virus and have
analysed the humoral response generated after immunisation. The recombinant vaccines elicited good
levels of protection in the knock-out mouse and the antibody response in IFNR−/− mice was similar to
that observed in vaccinated wild-type mice. These results indicate that the IFNR−/− mouse is a relevant
small animal model for studying ebolavirus-speciﬁc therapeutics.
& 2014 Published by Elsevier Inc.Introduction
The Ebolavirus genus is contained within the Filoviridae family
and consists of enveloped viruses with non-segmented, single-
strand, negative-sense RNA genomes (Sanchez et al., 2007).
Serological and genetic analysis has identiﬁed ﬁve distinct species
of ebolavirus: Zaire ebolavirus, Sudan ebolavirus, Taï Forest ebola-
virus, Reston ebolavirus and Bundibugyo ebolavirus (Falzarano et al.,
2011; Towner et al., 2008). Ebolaviruses can cause outbreaks of
severe haemorrhagic fever in humans and non-human primates
with up to 90% fatality rates reported in humans (Feldmann et al.,
2003). Transmission of ebolaviruses is generally due to direct
contact with blood, secretions or infected tissues although there is
also evidence for an airborne route of infection (Jaax et al., 1995;
Johnson et al., 1995; Roels et al., 1999).
Licensed vaccines and antivirals are currently not available for
the treatment of ebolaviruses but there is an urgent requirement
for their development due to continual sporadic outbreaks and the
potential for use in a bioterrorist attack (Borio et al., 2002).
Although non-human primates are believed to be the animal
model most representative of human disease (Bente et al., 2009;
Bray and Paragas, 2002), ethical, practical and ﬁnancial considerationslsevier Inc.
n).have meant that initial efﬁcacy screening has commonly been
performed in small animal models. Unlike non-human primates,
guinea pigs and adult immunocompetent mice are not susceptible
to infection with naturally occurring ebolaviruses and this has led
to the development of host-adapted viruses which are able to
cause lethal disease in these small animals. Thus, therapeutics for
ebolaviruses are often initially tested against adapted virus in a
mouse or guinea pig model. They may then progress to testing in
non-human primates (Rhesus and Cynomolgus macaques or
African green monkeys) if efﬁcacy is observed (Bente et al.,
2009). However, positive results obtained with adapted viruses
in small animal models have generally not translated into success-
ful outcomes against ebolaviruses in the non-human primate
model (Falzarano et al., 2011; Geisbert et al., 2002).
The current and most extensively used murine model employs
a mouse-adapted strain of Ebola virus (Bray et al., 1998). Adapta-
tion to mice through sequential passage resulted in a number of
nucleotide changes in both coding and non-coding regions of the
viral genome (Ebihara et al., 2006). The mutations principally
affected the ability of Ebola virus to overcome the type I interferon
(IFN) response but other mutations also contributed to the virulent
phenotype. Consequently, mouse-adapted Ebola virus does not
reﬂect natural viral properties. Whilst there are some biochemical
and pathological similarities between mice infected with the
adapted virus and those observed in non-human primates infected
with wild-type Ebola virus (EBOV), certain differences are observed,
Fig. 1. Detection of EBOV antigen expression by immunoﬂuorescence. HEK 293
cells infected with RAd/GP (a), RAd/sGP (b) or RAd/ssGP (c) were ﬁxed in cold
acetone and stained with polyclonal anti-EBOV followed by anti-rabbit IgG (whole
molecule) conjugated to FITC. Images of representative ﬁelds of view under UV
illumination were captured using a confocal microscope.
L.M. O'Brien et al. / Virology 452-453 (2014) 324–333 325for example in levels of ﬁbrin deposition (Bray et al., 2001).
Additionally, the adapted virus is only lethal to mice when admi-
nistered by the intraperitoneal route (Bente et al., 2009) whereas
non-human primates are susceptible to infection by multiple
routes. This small animal model therefore has considerable
limitations.
Although the precise mechanisms of ebolavirus disease are not
known, the inhibition of type I IFN responses is believed to be
crucial. Indeed, ebolaviruses encode two viral proteins, VP24 and
VP35, that block IFN responses (Ramanan et al., 2011). Treatment
of non-human primates with IFN-α2b prolonged survival and
delayed the development of viraemia (Jahrling et al., 1999) and,
in humans, it has been shown that fatal infections with EBOV are
associated with a lack of an IFN α2 response (Wauquier et al.,
2010). The resistance of adult immunocompetent mice to ebola-
virus infection is believed to be a consequence of the robust innate
immune response, particularly the type I IFN response, of these
animals (Bray, 2001; Ebihara et al., 2006). A more suitable small
animal model of human infection would initiate a less vigorous
innate immune response upon administration of ebolavirus.
Accordingly, an alternative murine model of ebolavirus infection
utilises the IFN α/β receptor knock-out (IFNR−/−) mouse (Müller
et al., 1994). EBOV is able to establish a lethal infection in this
model by either the intraperitoneal (Bente et al., 2009; Lever et al.,
2012), subcutaneous (Bente et al., 2009) or aerosol route (Lever
et al., 2012). The pathology of infection in the IFNR−/− mouse is
similar to that observed in non-human primates infected with
ebolaviruses by various routes (Lever et al., 2012) and encom-
passes characteristic pathological features observed in humans
(Lever et al., 2012). In addition to susceptibility to infection with
EBOV, this mouse strain has been shown to be susceptible to
Sudan virus (Bray, 2001) as well as Marburg virus (Bray, 2001;
Lever et al., 2012).
As a ﬁrst step in determining whether the IFNR−/− mouse could
be a more appropriate small animal model for ebolavirus infection
than the use of adapted virus in adult immunocompetent mice, we
investigated the ability of this knock-out mouse strain to respond to
adenovirus vectors expressing full-length and truncated forms of
EBOV glycoprotein (GP). The GP gene of ebolaviruses has three
overlapping open-reading frames which encode three proteins: GP,
secreted glycoprotein (sGP) and secondary secreted glycoprotein
(ssGP). The transmembrane surface GP, which mediates receptor
binding and membrane fusion, is only produced after transcrip-
tional RNA editing of the GP gene and proteolytic processing
(Sanchez et al., 1996; Volchkov et al., 1998). The principal product
of the GP gene is the non-structural sGP which is expressed from
non-edited mRNA (Volchkova et al., 1998). sGP is secreted from
infected cells and shares the N-terminal 295 amino acids with GP
but differs in the C-terminal by 69 amino acids (Volchkova et al.,
1998). Another editing product of the GP gene, ssGP, is also secreted
from cells and shares the 295 N-terminal amino acids with sGP but
lacks the C-terminal amino acids (Volchkova et al., 1998). During
virus replication in vivo, 67% of GP gene-speciﬁc mRNAs direct
synthesis of sGP, 31% direct expression of GP and 2% direct
expression of ssGP (Mehedi et al., 2011). We constructed recombi-
nant human adenovirus type 5 (RAd) expressing GP, sGP or ssGP
and tested the ability of each vaccine to protect IFNR−/− mice from
EBOV infection. Adenovirus-vectored GP is known to protect non-
human primates from ebolavirus infection (Pratt et al., 2010;
Sullivan et al., 2006; Swenson et al., 2008) and was chosen for this
work as an established efﬁcacious vaccine. However, the protective
efﬁcacy of sGP or ssGP has not been investigated. The humoral
response of vaccinated IFNR−/− mice was also compared to that
generated in mice of the wild-type (WT) parental strain to deter-
mine how the absence of an IFN α/β receptor affected the antibody
response to the three recombinant vaccines.Results
RAd/GP, RAd/sGP and RAd/ssGP express the full-length and
truncated variants of GP
The expression of viral glycoprotein antigen was conﬁrmed by
staining cells infected with either RAd/GP, RAd/sGP or RAd/ssGP
with rabbit polyclonal anti-EBOV immunoglobulin (Fig. 1). Fluor-
escence was not observed with cells infected with the empty
adenovirus vector, RAd (results not shown).
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Fig. 2. Protection against intraperitoneal EBOV challenge. IFNR−/− mice (n¼10)
were immunised intranasally with 1107 pfu RAd (♦), RAd/GP ( ), RAd/sGP ( ) or
RAd/ssGP ( ) on days 0, 7 and 21 prior to challenge on day 40 with 10 TCID50 EBOV.
Mice were monitored for 21d and were culled when appropriate.
L.M. O'Brien et al. / Virology 452-453 (2014) 324–333326Immunisation with recombinant adenoviruses protects
against EBOV challenge
Once antigen expression had been veriﬁed, the ability of RAd/
GP, RAd/sGP and RAd/ssGP to protect IFNR−/− mice from disease
was determined. Mice were immunised by the intranasal route
with three doses of RAd, RAd/GP, RAd/sGP or RAd/ssGP on days 0,
7 and 21 (a vaccination schedule shown to be effective previously
with other recombinant adenoviruses; Phillpotts et al., 2005). The
animals were intraperitoneally challenged on day 40 with approxi-
mately 10 LD50 EBOV strain E718 (work with EBOV [unpublished]
and Marburg virus [Smither et al., 2013] indicates that the LD50 in
IFNR−/− mice is equivalent to that in common marmosets). Mice
vaccinated with RAd did not survive the challenge dose (Fig. 2). In
contrast, signiﬁcant (Po0.0001) levels of protection from EBOV
disease were observed in mice that had been immunised with
RAd/GP, RAd/sGP or RAd/ssGP (100%, 60% and 40% survival rates,
respectively; Fig. 2). The protection induced by RAd/GP vaccination
was signiﬁcantly higher than that induced by RAd/sGP (Po0.05)
or RAd/ssGP (Po0.005) vaccination. The levels of protection
induced by RAd/sGP and RAd/ssGP were not signiﬁcantly different
(P40.05).
Immunisation with RAd/GP, RAd/sGP and RAd/ssGP elicits cross-
reactive antibody
In order to test the speciﬁcity of sera generated by the three
recombinant vaccines, immune sera were utilised in Western blot
protocols with recombinant GP or supernates collected from cells
infected with RAd/sGP and RAd/ssGP (Fig. 3). Sera harvested from
IFNR−/− mice immunised with RAd/GP, RAd/sGP or RAd/ssGP
reacted with recombinant GP (approximately 150 kDa) and with
proteins present in the supernates of infected cells (approximately
50 kDa). These bands correspond to the size of sGP and ssGP. Mice
vaccinated with RAd did not react with either recombinant GP or
supernatant proteins (results not shown). Vaccination with any of
the three recombinant adenoviruses therefore generated antibody
capable of reacting with GP, sGP or ssGP.Characterisation of the B-cell response following vaccination
It is clear that IFNR−/− mice can respond to immunisation with
recombinant adenoviruses by generating a level of immunity
capable of overcoming challenge with EBOV. However, it is not
known if the lack of an IFN α/β receptor has any impact on the
immune response compared to that induced in WT mice onadministration of the recombinant vaccines. Any differences
between the induction of immunity in the IFNR−/− mouse and
the WT mouse should be elucidated to ensure that the IFNR−/−
mouse remains a suitable candidate for a small animal model of
ebolavirus infection. Both humoral and cellular immune responses
contribute to the immune response following vaccination (Warﬁeld
and Olinger, 2011) but the precise mechanism of protection is
currently unknown. However, multiple vaccine studies have shown
that the generation of ebolavirus-speciﬁc antibodies correlates with
protection (Falzarano et al., 2011 and references within; Marzi et al.,
2013; Wong et al., 2012) and survival can be reliably predicted
when IgG titres reach a certain level in non-human primates
vaccinated with a recombinant adenovirus (Sullivan et al., 2009).
IFNR−/− and WT mice were therefore vaccinated with RAd/GP, RAd/
sGP and RAd/ssGP in order to compare the generation of EBOV-
speciﬁc antibody responses.
Isotype proﬁle of immune sera
Sera were harvested 13 days after the third immunisation of
each recombinant adenovirus (day 34). The concentration of EBOV-
speciﬁc IgG1, IgG2a, IgG2b and IgG3 was then determined by ELISA
(Fig. 4). In both IFNR−/− and WT mice, all three vaccines induced a
similar response pattern with IgG1 and IgG2a being the principal
isotypes. IgG2b and IgG3 were also induced by vaccination, in
particular by RAd/GP. Although the isotype proﬁle of IFNR−/− and
WT mice appeared very similar, some evidence for modest differ-
ences was observed. A small but statistically signiﬁcant (Po0.05)
reduction in IgG2a concentration was detected in IFNR−/− mice as
compared to WT mice. No signiﬁcant differences were discerned in
the concentrations of IgG1, IgG2b and IgG3 between IFNR−/− and
WTmice (P40.05 in all cases). Therefore, the absence of the IFN α/β
receptor does not greatly affect the class of antibody produced
when IFNR−/− mice are immunised with RAd/GP, RAd/sGP and RAd/
ssGP. The high levels of both IgG1 and IgG2a, in particular in WT
mice, indicate a balanced response to the glycoprotein antigens
rather than an immune bias, although the signiﬁcantly lower levels
of IgG2a in IFNR−/− mice may indicate a less balanced immune
response that is tending towards a TH2 bias.
Identiﬁcation of linear B-cell epitopes within GP, sGP and ssGP
Synthetic peptide libraries, consisting of 15-mer peptides that
overlap by 10 amino acids, were created from the three glycopro-
teins. Due to the overlapping open-reading frames of the GP gene,
the ﬁrst 57 peptides of each library were identical. Peptides
subsequent to the 57th peptide were speciﬁc for each library.
However, the 58th peptide of the sGP library (designated peptide
59) and of the ssGP library (designated peptide 60) possessed 73%
and 67% sequence identity, respectively, to peptide 58 of the GP
library. In addition to the shared 57 peptides, the GP library
contained 77 peptides (although the two C-terminal peptides
were excluded from the analysis because of a failure in quality
control) and the sGP library contained 14 peptides. The ssGP
library consisted of the shared 57 peptides plus peptide 60 only.
A total of 30 serum samples, harvested on day 34 from groups
of ﬁve WT and ﬁve IFNR−/−mice immunised with each of the three
recombinant vaccines, were tested for reactivity to GP-, sGP- or
ssGP-derived peptides that had been immobilised on microarrays.
Positive responses were deﬁned as normalised average signal
intensities three times greater than the average signal intensity
of the negative control features within the microarray. Excluding
the ﬁrst 58 peptides of each library, sera were generally speciﬁc for
peptides derived from the protein used as the immunogen. Sera
from one WT mouse immunised with RAd/GP bound to a peptide
belonging exclusively to the sGP library, sera from one WT mouse
immunised with RAd/sGP bound to ﬁve peptides belonging
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Fig. 3. Detection of EBOV GP, sGP and ssGP with polyclonal sera from immunised mice. Recombinant GP (rGP) or proteins present in supernates harvested from HEK
293 cells infected with RAd/sGP (sGP) or RAd/ssGP (ssGP) were resolved on a 4–20% gradient polyacrylamide gel under denaturing and reducing conditions. Membranes
were probed with pooled sera from IFNR−/− mice immunised with RAd/GP, RAd/sGP or RAd/ssGP. Scale indicates size in kDa.
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Fig. 4. Quantity of EBOV-speciﬁc IgG isotypes present in the sera of mice
immunised intranasally with recombinant adenoviruses. IFNR−/− and WT mice
were immunised with 1107 pfu RAd/GP, RAd/sGP or RAd/ssGP on days 0, 7 and
21. Sera were collected on day 34 and assayed for anti-EBOV IgG isotypes (n¼4, 95%
conﬁdence intervals are shown).
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with RAd/ssGP bound to a total of three peptides belonging
exclusively to the GP library. As these responses showed low signal
intensities and were only detectable at the lowest serum dilution
tested they were excluded from further analysis.
Figs. 5–7 show the number of positive responses to each
peptide within each library. In general, the pattern of binding
within each library was similar for both WT and IFNR−/− sera. In
fact, signiﬁcant differences between WT and IFNR−/− sera were
only observed for peptides 95 (Po0.05) and 103 (Po0.01) in the
GP library (Fig. 5). However, a signiﬁcantly greater number of
positive responses was obtained overall with immune sera from
WT mice compared to IFNR−/− mice (Po0.001) and signal inten-
sities were usually stronger in samples obtained from WT mice
(results not shown). Further interrogation of the data indicated
that the difference in the number of positive responses between
WT and IFNR−/− sera was only statistically signiﬁcant in RAd/GP
vaccinated mice (Po0.005, Po0.01 with Bonferroni's correction
for multiple tests), although it is conceivable that the difference in
this group is more pronounced because it has the greatest number
of linear epitopes.
Whilst positive responses to GP and ssGP peptides were dis-
persed throughout the libraries (Figs. 5 and 7), the positive
responses in the sGP library were quite distinct and were restricted
principally to peptides 38 and 39 and peptides 57 and 59 (Fig. 6).As sera from RAd/GP- and RAd/ssGP-vaccinated mice also reacted
strongly to peptides in these two areas of the libraries' shared
region (Figs. 5 and 7, respectively), it is highly likely that they
contain the sequences for linear B-cell epitopes. Peptide 38
(LPQAKKDFFSSHPLR), peptide 39 (KDFFSSHPLREPVNA) and peptide
57 (IDTTIGEWAFWETKK) reacted with the majority of serum
samples (29/30, 27/30 and 30/30, respectively). As peptide 57
overlaps with peptide 58 (GEWAFWETKKNLTRK) and shares
sequence identity with peptides 59 (GEWAFWETKKTSLEK) and 60
(TTIGEWAFWETKKPH), the number of positive responses to these
peptides was also high (Figs. 5–7). However, in the majority of
cases, the highest signal intensities were obtained with peptides 38
and 57 (results not shown). It can also be hypothesised that linear
B-cell epitopes are contained within peptides 9–10, 63, 78, 93–96,
103, 108–113, 117, 121–122 and 140–141 of the GP library (Fig. 5),
within peptide 82 of the sGP library (Fig. 6) and within peptides
9–10, 16–21, 26 and 49–50 of the ssGP library (Fig. 7). Thus,
immunisation with RAd/GP, RAd/sGP and RAd/ssGP leads to the
generation of sera that can recognise shared linear epitopes between
the three proteins but that is also capable of recognising distinct
linear epitopes, dependent on the protein used as the immunogen.
Tables 1–3 show the frequency of positive responses generated
with each serum sample. The results have been recorded so that
responses to the peptides shared between the three libraries and
responses to those parts of the libraries that are speciﬁc to each
protein can be distinguished. As the 58th peptide of each library
shows high sequence homology to the last peptide in the shared
region, it has been included in these results. When sera harvested
from mice immunised with RAd/GP were tested, many more
peptides in the GP-speciﬁc area of the library were recognised
than in the shared region (Po0.001; Table 1). In contrast, RAd/sGP
sera preferentially bound to peptides in the shared region rather
than peptides in the speciﬁc area of the library (Po0.05; Table 2).
Sera obtained from mice immunised with RAd/ssGP bound to
many peptides in the shared region (Table 3).Discussion
The development of antiviral treatments and vaccines for the
prevention of disease caused by ebolaviruses has been the focus of
research for a number of years. Thus far, limited progress has been
made in the development of effective antiviral drugs (de Wit et al.,
2011). Potential therapeutics include small molecule inhibitors
(Aman et al., 2009; Wolf et al., 2010), monoclonal antibodies, tissue
factor inhibitors, phosphorodiamidate morpholino oligomers (Bausch
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Fig. 5. Reactivity of polyclonal sera to EBOV GP peptides. Groups of ﬁve IFNR−/− and ﬁve WT mice were immunised with RAd/GP on days 0, 7 and 21. Sera were harvested on
day 34 and incubated with peptides derived from GP. The ﬁgures (A)–(C) show the number of mice reacting to each peptide. Signiﬁcant differences between WT and IFNR−/−
sera are indicated (*Po0.05; **Po0.01).
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(Geisbert et al., 2010). Classical vaccine approaches, such as inacti-
vated virus with different adjuvants, were generally not successful in
protecting non-human primates from a lethal challenge with ebola-
viruses (de Wit et al., 2011). This led to the development of
recombinant ebolavirus vaccines which are based on delivery plat-
forms such as DNA, viral vectors and virus-like particles (Falzarano
et al., 2011; de Wit et al., 2011). There are advantages to using viral
vectors such as human adenovirus type 5 (Croyle et al., 2008; Patel
et al., 2007), human parainﬂuenza virus type 3 (Bukreyev et al., 2007)
and Newcastle disease virus (DiNapoli et al., 2011) that have a natural
tropism for the respiratory tract as administration of these recombi-
nant vaccines generates a systemic immune response as well as a
mucosal response, thereby providing protection against direct con-
tact and the airborne route of infection. In addition to the evidence to
suggest that there may be natural aerosol transmission of ebola-
viruses (Jaax et al., 1995; Johnson et al., 1995; Roels et al., 1999), the
most likely route of infection during a bioterrorism event would be
by the airborne route.
It has been reported that a number of vaccines (including RNA
replicon particles expressing ebolavirus GP plus nucleoprotein and
recombinant vaccinia virus expressing ebolavirus GP) that had
successfully protected mice or guinea pigs from lethal ebolavirus
infection with adapted virus were subsequently shown to be
ineffective when administered to non-human primates (Geisbert
et al., 2002). Progress in the development of efﬁcacious therapeu-
tics for ebolaviruses may therefore have been hindered by the
limitations of the current small animal models that utilise adapted
virus. The ability of recombinant adenovirus vaccines to induceprotective levels of immunity in the IFNR−/− mouse indicates that
this knock-out mouse has the potential to be a more suitable small
animal model for the study of medical countermeasures to
ebolaviruses. The ability to test therapeutics against naturally
occurring viral species has more relevance for non-human primate
models of disease and it may therefore accurately predict the
outcome of experiments in these non-human primate models.
However, the IFNR−/− mouse would not be an appropriate model
for testing antiviral drugs that exert their activity through IFN-α or
-β signalling.
Recombinant adenoviruses are attractive vaccine delivery plat-
forms because they are able to induce high levels of speciﬁc antibody
and strong CD4+ and CD8+ T-cell responses to the transgene.
Adenovirus-vectored GP has already been shown to be a successful
vaccine in non-human primates (Pratt et al., 2010; Sullivan et al.,
2006; Swenson et al., 2008) and has been tested in a phase I clinical
trial where it was shown to be safe, well tolerated and immunogenic
in the presence or absence of pre-existing adenovirus immunity
(Ledgerwood et al., 2011). The utility of an adenovirus-based vaccine
expressing GP, as well as vaccines expressing sGP and ssGP, has now
been demonstrated in the IFNR−/− mouse. The reason(s) for the
different levels of protection with each vaccine was not deﬁnitively
ascertained in this study. IFNR−/−mice immunised with RAd/sGP and
RAd/ssGP exhibited much lower levels of IgG3 compared to those
mice immunised with RAd/GP. This may have abrogated Fc-mediated
effector functions such as antibody-dependent cellular cytotoxicity
and complement-dependent cytotoxicity. Sera from IFNR−/− mice
immunised with RAd/GP showed a bias in the antibody response
to peptides within GP, generally reacting with a higher frequency
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Fig. 6. Reactivity of polyclonal sera to EBOV sGP peptides. Groups of ﬁve IFNR−/− and ﬁve WT mice were immunised with RAd/sGP on days 0, 7 and 21. Sera were harvested
on day 34 and incubated with peptides derived from sGP. The ﬁgures (A) and (B) show the number of mice reacting to each peptide.
L.M. O'Brien et al. / Virology 452-453 (2014) 324–333 329to peptides in the GP-speciﬁc region. In contrast, RAd/sGP sera
reacted with low frequency to peptides in both the shared region
of the GP proteins and the sGP-speciﬁc region whilst RAd/ssGP sera
could in the main only react with peptides in the shared region. The
presence of antibodies that recognised peptides within the speciﬁc
region of GP may therefore also have contributed to the superior
protection elicited by the RAd/GP vaccine in IFNR−/− mice.
Fundamentally, the humoral immunity generated by vaccina-
tion with RAd/GP, RAd/sGP and RAd/ssGP was the same in IFNR−/−
mice as WT mice and the absence of the IFN α/β receptor did not
have a considerable impact on the antibody response. However,
there were two areas of humoral immunity where the absence of
the IFN α/β receptor did have a statistically signiﬁcant effect. First,
the IFNR−/− mice produced marginally less IgG2a in response to
vaccination. This is consistent with reports that IFN-α promotes a
bias towards a TH1 immune response (Huber and Farrar, 2011 and
references within) but as the reduction in IgG2a was so small it
can be hypothesised that other factors contribute to immune
biasing. Second, there was a signiﬁcant decrease in the number
of positive responses to peptides by IFNR−/− sera. The reason for
this is unclear but there was little evidence to suggest that,
compared to WT mice, IFNR−/− mice have an altered preferencefor linear B-cell epitopes. It is possible that IFNR−/− mice possess
less B-cell diversity or that fewer B-cells in IFNR−/− mice are being
activated upon vaccination. We feel that the latter possibility is
more likely as lower concentrations of antibody were produced. In
summary, the data suggest that signalling through the IFN α/β
receptor plays a small role in the instigation of the humoral
immune response to these recombinant vaccines.
A number of recent studies have demonstrated the essential
role of antibodies in the immunity of non-human primates to
ebolavirus infection. Passive immunisation with virus-speciﬁc
antibodies protected non-human primates from ebolavirus infec-
tion (Dye et al., 2012; Marzi et al., 2012; Olinger et al., 2012; Qiu
et al., 2012) and survival of vaccinated non-human primates
correlated with the production of GP-speciﬁc antibodies (Marzi
et al., 2013; Wong et al., 2012). However, it has previously been
shown that protection of wild-type mice against infection with
host-adapted virus requires activation of both humoral and cel-
lular immune responses (Warﬁeld et al., 2005). In this study we
did not examine T-cell responses and so cannot make any conclu-
sions as to how the absence of the IFN α/β receptor affects the
cellular immune response or the role of T-cells in vaccine-
mediated protection against ebolavirus in this mouse model. For
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Fig. 7. Reactivity of polyclonal sera to EBOV ssGP peptides. Groups of ﬁve IFNR−/−
and ﬁve WT mice were immunised with RAd/ssGP on days 0, 7 and 21. Sera were
harvested on day 34 and incubated with peptides derived from ssGP. The ﬁgure
shows the number of mice reacting to each peptide.
Table 1
Groups of ﬁve IFNR−/− and ﬁve WT mice were immunised with RAd/GP on days 0,
7 and 21. Sera were harvested on day 34 and tested for reactivity with peptides
derived from EBOV glycoproteins. The P-values are Fisher's exact test comparisons
of the frequency of epitopes in the shared region compared to those in the
GP-speciﬁc region.
Serum
sample
Frequency of positive responses
Shared region GP-speciﬁc
region
Peptide 59 of
sGP library
Peptide 60 of
ssGP library
WT 5/57 19/75(Po0.05) 1/1 1/1
WT 6/57 20/75(Po0.05) 1/1 1/1
WT 4/57 24/75(Po0.001) 1/1 1/1
WT 7/57 18/75(P40.05) 1/1 1/1
WT 6/57 21/75(Po0.05) 1/1 1/1
IFNR−/− 4/57 12/75(P40.05) 1/1 1/1
IFNR−/− 4/57 17/75(Po0.05) 0/1 1/1
IFNR−/− 5/57 16/75(P40.05) 1/1 1/1
IFNR−/− 3/57 8/75(P40.05) 1/1 1/1
IFNR−/− 2/57 13/75(Po0.05) 1/1 1/1
Table 2
Groups of ﬁve IFNR−/− and ﬁve WT mice were immunised with RAd/sGP on days 0,
7 and 21. Sera were harvested on day 34 and tested for reactivity with peptides
derived from EBOV glycoproteins. The P-values are Fisher's exact test comparisons
of the frequency of epitopes in the shared region compared to those in the sGP-
speciﬁc region.
Serum
sample
Frequency of positive responses
Shared
region
sGP-speciﬁc
region
Peptide 58 of
GP library
Peptide 60 of
ssGP library
WT 3/57 1/14(P40.05) 1/1 1/1
WT 5/57 3/14(P40.05) 1/1 1/1
WT 4/57 2/14(P40.05) 1/1 1/1
WT 4/57 1/14(P40.05) 1/1 1/1
WT 11/57 3/14(P40.05) 1/1 1/1
IFNR−/− 3/57 2/14(P40.05) 1/1 1/1
IFNR−/− 4/57 1/14(P40.05) 1/1 1/1
IFNR−/− 2/57 1/14(P40.05) 1/1 1/1
IFNR−/− 4/57 2/14(P40.05) 1/1 1/1
IFNR−/− 6/57 1/14(P40.05) 1/1 1/1
Table 3
Groups of ﬁve IFNR−/− and ﬁve WT mice were immunised with RAd/ssGP on days 0,
7 and 21. Sera were harvested on day 34 and tested for reactivity with peptides
derived from EBOV glycoproteins.
Serum
sample
Frequency of positive responses
Shared
region
ssGP-speciﬁc
region
Peptide 58
of
GP library
Peptide 59
of
sGP library
WT 10/57 1/1 1/1 1/1
WT 23/57 1/1 1/1 1/1
WT 12/57 1/1 0/1 0/1
WT 20/57 1/1 1/1 1/1
WT 14/57 1/1 1/1 1/1
IFNR−/− 11/57 1/1 1/1 1/1
IFNR−/− 5/57 0/1 0/1 0/1
IFNR−/− 5/57 1/1 0/1 0/1
IFNR−/− 10/57 1/1 0/1 0/1
IFNR−/− 12/57 1/1 1/1 1/1
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and to allow comparisons with the wild-type mouse model and
non-human primate model, analysis of the T-cell responses in
IFNR−/− mice is required and will be the subject of future work.
Two areas within the shared 295 N-terminal amino acids of GP,
sGP and ssGP appeared to contain linear B-cell epitopes common
to the three proteins. The cross-reactivity of immune sera in
Western blots can be attributed to antibodies speciﬁc for these
two regions. However, potential linear B-cell epitopes were also
identiﬁed that were speciﬁc to the immunogen used. This may be
due to the fact that GP, sGP and ssGP differ in their glycosylation
patterns, and thus their tertiary structures, which likely affects the
availability of epitopes (Mehedi et al., 2011 and references within).The use of the IFNR−/− mouse as a small animal model for
evaluating medical countermeasures to other viruses is increasing.
For example, it currently offers the only animal model for studying
disease caused by Crimean–Congo hemorrhagic fever virus (Zivcec
et al., 2013) and it provides an alternative to ruminant animal
L.M. O'Brien et al. / Virology 452-453 (2014) 324–333 331models for the study of Schmallenberg virus (Wernike et al., 2012)
and Bluetongue virus (Calvo-Pinilla et al., 2009). Although other
knock-out mouse strains have been tested for their suitability as
small animal models for ﬁlovirus infection (Bray, 2001; Raymond
et al., 2011), the majority of research has been performed with the
IFNR−/− mouse. It is now known that this strain is susceptible to
the airborne route of infection (Lever et al., 2012) and that the
mice can be protected from challenge with naturally occurring
ebolaviruses by vaccination with recombinant adenoviruses. The
protective mechanisms against infection with naturally occurring
ebolaviruses can now be elucidated in the IFNR−/− mouse model
and compared to the mechanisms of protection in non-human
primates (Sullivan et al., 2011). This will provide further evidence
of the relevance of the IFNR−/− mouse as a small animal model for
ebolavirus infection. In addition, other ﬁlovirus therapeutics, that
have already been shown to be effective in non-human primates
(Bradfute and Bavari, 2011 and references within; de Wit et al.,
2011 and references within), should be tested in the IFNR−/−
mouse. The results of these studies will allow a decision to be
made on the future use of the IFNR−/− mouse as a small animal
model for infection with naturally occurring ﬁloviruses.Materials and methods
Reagents, cells and viruses
All reagents were supplied by Sigma (UK) unless indicated
otherwise. The HEK 293 (human embryonic kidney) and Vero
C1008 (simian kidney) cell lines (European Collection of Animal
Cell Cultures, UK) were propagated by standard methods using the
recommended culture media. The EBOV GP, sGP and ssGP
sequences (NCBI accession numbers AAB81004.1, NP_066247.1
and NP_066248, respectively) were gene optimised for mamma-
lian expression and synthesised by GeneArt (Life Technologies,
UK). The three DNA sequences were cloned into the pShuttle-CMV
vector (supplied in the AdEasy™ Adenoviral Vector system;
Agilent Technologies, UK). RAds expressing GP, sGP and ssGP were
then constructed using the AdEasy™ Adenoviral Vector system
and were designated RAd/GP, RAd/sGP and RAd/ssGP, respectively.
The empty adenovirus vector (RAd) has been described previously
(Phillpotts et al., 2005) and was used in experiments as a negative
control. Stocks of recombinant adenoviruses were produced by
The Native Antigen Company (UK). Human-derived EBOV strain
E718 (Ellis et al., 1979) was kindly supplied by Dr G Lloyd (Health
Protection Agency, Porton Down, UK). EBOV was propagated in
Vero C1008 cells for 7d prior to harvesting of infected tissue-
culture supernate and clariﬁcation by centrifugation at 900 g for
15 min. Clariﬁed supernate was titrated by end-point dilution
assay (Lever et al., 2012) in 96-well cell culture microplates
(Corning Incorporated, USA). The 50% tissue-culture infectious
dose (TCID50) was calculated from the proportion of infected wells
at each dilution using the formula of Reed and Muench (1938).
All work with live EBOV was performed under UK Advisory
Committee on Dangerous Pathogens (ACDP) and UK Scientiﬁc
Advisory Committee on Genetic Modiﬁcation (SACGM) Level
4 containment (Smither and Lever, 2012).
Immunoﬂuorescence
RAds were tested for expression of GP, sGP or ssGP by immuno-
ﬂuorescence. HEK 293 cells were infected with RAd, RAd/GP, RAd/
sGP or RAd/ssGP for 24 h at a multiplicity of infection (moi) of 1000.
Cells were then harvested, washed twice in PBS by centrifugation
and resuspended in PBS. The suspension (5 μl) was spotted onto
glass slides (CA Hendley Ltd., UK) which were then air dried andﬁxed in acetone at −20 1C for 15 min. The ﬁxed cells were reacted for
1 h at 37 1C with 10 μg/ml polyclonal anti-EBOV (generated by
immunising a rabbit with gamma-irradiated EBOV) in PBS/1% (v/v)
foetal calf serum (FCS). After three washes in PBS, cells were stained
for 1 h at 37 1C with FITC-labelled goat anti-rabbit IgG (whole
molecule) diluted 1/1000 in PBS/1% (v/v) FCS. The slides were
washed a further four times in PBS before being mounted in 50%
(v/v) glycerol and examined under UV illumination.
Animals, immunisation and challenge with EBOV
IFNR−/− (A129) mice and mice from the parental strain (129S7/
SvEv; designated WT) were obtained from B&K Universal Ltd.
(UK). Adult mice, aged 6–16 weeks, were caged in separate groups
of males or females. IFNR−/− mice were housed in ﬂexible-wall
isolators within ACDP/SACGM Level 2 containment and WT mice
were housed in open cages within ACDP/SACGM Level 2 contain-
ment. Mice were immunised intranasally under halothane anaes-
thesia on days 0, 7 and 21 with 107 plaque forming units (pfu) RAd,
RAd/GP, RAd/sGP or RAd/ssGP in 50 μl PBS. Numbers of male and
female mice were distributed equally within treatment groups.
Prior to challenge, vaccinated mice were transferred to rigid-wall
isolators within ACDP/SACGM Level 4 containment and, 11d after
the ﬁnal immunisation (day 40), 10 TCID50 EBOV (equating to
approximately 1 plaque forming unit [pfu] and 10 50% lethal doses
[LD50]; Lever et al., 2012) were administered by the intraperitoneal
route in a volume of 100 ml. Infected mice were weighed daily and
observed twice daily for 21d for clinical signs (piloerection,
hunched posture, immobility, eye disorders) or mortality. Mice
exhibiting severe clinical signs were humanely culled. All animal
studies were performed in accordance with the UK Scientiﬁc
Procedures Act (Animals) 1986 and UK Codes of Practice for the
Housing and Care of Animals Used in Scientiﬁc Procedures 1989.
Western blot
HEK 293 cells were infected with RAd/sGP or RAd/ssGP (moi
100) and, after 24 h, supernates were harvested and centrifuged to
remove cell debris. Western blots were performed with either
recombinant GP or infected cell supernates. An equal volume of
recombinant GP (approximately 30 μg) or supernate and Laemmli
sample buffer were heated at 95 1C for 5 min. Proteins were
separated on a 4–20% polyacrylamide gel (Thermo Scientiﬁc, UK)
and transferred to a PVDF membrane (Invitrogen, UK). Non-
speciﬁc antibody-binding sites were blocked with 1% (w/v) skim
milk powder in PBS/0.1% (v/v) Tween-20 for 1 h. The membrane
was then incubated for 1 h with pooled serum samples from
IFNR−/− mice that had been vaccinated with RAd, RAd/GP, RAd/sGP
or RAd/ssGP (1/100 dilution in blocking buffer; sera obtained from
the marginal tail vein on day 24). After three washes in PBS/0.1%
(v/v) Tween-20, the membrane was incubated for 1 h with
peroxidase-conjugated goat anti-mouse IgG (whole molecule)
diluted to 1/100 in blocking buffer. Protein bands were visualised
using 3,3′-diaminobenzidine, after three washes in PBS/0.1% (v/v)
Tween-20.
Enzyme immunoassay
Enzyme immunoassay (ELISA) was performed by standard meth-
ods. Sera, obtained by cardiac puncture of vaccinated mice on day 34,
were assayed for speciﬁc antibodies using gamma-irradiated EBOV
antigen diluted to approximately 2107 pfu/ml in carbonate–bicar-
bonate buffer. The secondary antibodies were peroxidase-conjugated
goat anti-mouse IgG isotypes (AbD Serotec, UK) diluted to 1/4000.
Immunoglobulin concentrations were estimated by comparison of
L.M. O'Brien et al. / Virology 452-453 (2014) 324–333332the absorbance values generated by diluted serum samples with a
standard curve prepared from dilutions of murine IgG isotypes.
Binding of immune sera to peptide libraries
The reactivity of immune sera (obtained by cardiac puncture of
vaccinated mice on day 34) to peptides derived from the GP, sGP
and ssGP proteins was assessed by ProImmune (UK) using syn-
thetic peptide libraries (15-mer peptides, overlapping by 10 amino
acids) immobilised onto ProArray Ultra™ slides. The GP peptide
library consisted of 134 peptides, the sGP library of 71 peptides
and the ssGP library of 58 peptides (the numbers assigned to each
peptide within a library for identiﬁcation purposes are not sequen-
tial). Two peptides (numbers 148 [VIIAVIALFCICKFV] and 149 [IIA-
VIALFCICKFVF]) located at the extreme C-terminus of GP failed to
synthesise correctly and these peptides were discarded from further
analysis. Peptide microarrays were incubated with dilutions of sera
(1/200–1/60,000) harvested from IFNR−/− and WT mice immunised
with RAd/GP, RAd/sGP and RAd/ssGP, as described above, followed by
incubation with a ﬂuorescently-labelled anti-mouse IgG antibody
(DyLight 649 AfﬁniPure goat anti-mouse IgG [H+L], Jackson Immu-
noResearch Laboratories, USA). After several washing steps, the
arrays were dried and scanned using a high-resolution ﬂuorescence
microarray scanning system. Image analysis software was then used
to quantify the ﬂuorescence intensity associated with each ﬂuores-
cent spot on the microarray slide.
Statistical methods
Statistical analysis was performed by using SPSS software
(version18.0). Survival data were analysed using the Logrank test.
Data concerning the concentration of isotypes in sera were found
to be suitable for parametric analysis when transformed to the
logarithm of 10 by comparison to the normal distribution in
normal plots and Levene's tests for unequal variance. Antibody
concentration was then analysed by multivariate linear model
analysis. The frequency of epitopes was found to be suitable for
parametric analysis after normalisation to the maximum and an
arcsine transformation. Where multiple tests have been per-
formed, the Bonferroni's correction was used and reported. These
data were then analysed by univariate linear model analysis. Direct
comparison of the response of IFNR−/− and WT mice to each
epitope was compared by Fisher's exact test. In order to compare
the proportions of epitopes recognised in shared and speciﬁc
regions, two methods were used. First, data were prepared by
calculating the proportion of the recognised to unrecognised
peptides for each serum sample and transformed using arcsine;
this rendered the data suitable for parametric analysis (conﬁrmed
by comparison to the normal distribution in normal plots and
Levene's tests for unequal variance). The data were then analysed
by a repeated measures univariate linear model. Also, individual
serum samples were compared by Fisher's exact test. At no point
was there statistical evidence to suggest that gender affected
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